RevenueThe total money the company brought in from sales, before subtracting any costs.
$605Mβ² +37.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
59.9%β² +0.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnβt profitable yet.
$109Mβ² +189.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$134MβΌ β265.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerβs slice.
40.9Mβ² +16.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$19Mβ² +$200M YoY
StockOtter Β· stockotter.space
About TRANSMEDICS GROUP INC
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
π¦¦
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)